Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study

The Lancet Psychiatry

Volumn 6, Issue 8, 2019, Pages 651-658

  Hollis, Chris ^a   Chen, Qi ^b   Chang, Zheng ^b   Quinn, Patrick D ^c   Viktorin, Alexander ^b   Lichtenstein, Paul ^b   D'Onofrio, Brian ^b,c   Landén, Mikael ^b,d   Larsson, Henrik ^b,e  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e ÖREBRO UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; HOSPITAL PATIENT; HUMAN; ICD-10; MALE; OBSERVATIONAL STUDY; OUTPATIENT; PATIENT CODING; POPULATION; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; TREATMENT DURATION; YOUNG ADULT; ATTENTION DEFICIT DISORDER; DRUG SURVEILLANCE PROGRAM; INCIDENCE; SWEDEN;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; METHYLPHENIDATE; PHARMACOVIGILANCE; PSYCHOSES, SUBSTANCE-INDUCED; SWEDEN; YOUNG ADULT;

EID: 85070180567     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(19)30189-0     Document Type: Article

References (25)

1. Dalsgaard, S, Mortensen, PB, Frydenberg, M, Maibing, CM, Nordentoft, M, Thomsen, PH, Association between attention-deficit hyperactivity disorder in childhood and schizophrenia later in adulthood. Eur Psychiatry 29 (2014), 259–263.
2. Kim-Cohen, J, Caspi, A, Moffitt, TE, Harrington, H, Milne, BJ, Poulton, R, Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective longitudinal cohort. Arch Gen Psychiatry 60 (2003), 709–717.
3. Thapar, A, Martin, J, Mick, E, et al. Psychiatric gene discoveries shape evidence on ADHD's biology. Mol Psychiatry 21 (2016), 1202–1207.
4. Peralta, V, de Jalon, EG, Campos, MS, Zandio, M, Sanchez-Torres, A, Cuesta, MJ, The meaning of childhood attention-deficit hyperactivity symptoms in patients with a firstepisode of schizophrenia-spectrum psychosis. Schizophr Res 126 (2011), 28–35.
5. MacKenzie, LE, Abidi, S, Fisher, HL, et al. Stimulant medication and psychotic symptoms in offspring of parents with mental illness. Pediatrics, 137, 2016.
6. Cressman, AM, Macdonald, EM, Huang, A, et al. Prescription stimulant use and hospitalization for psychosis or mania: a population-based study. J Clin Psychopharmacol 35 (2015), 667–671.
7. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management (NICE guideline NG87). https://www.nice.org.uk/guidance/ng87, 2018. (Accessed 27 May 2019)
8. Arnsten, AF, Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology 31 (2006), 2376–2383.
9. Howes, OD, Kambeitz, J, Kim, E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 69 (2012), 776–786.
10. Tost, H, Alam, T, Meyer-Lindenberg, A, Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes. Neurosci Biobehav Rev 34 (2010), 689–700.
11. Vigilance and Intelligence Research Group, Medicines and Healthcare Products Regulatory Agency. Yellow Card scheme interactive drug analysis profiles. http://www.mhra.gov.uk/drug-analysis-prints/drug-analysis-prints-a-z/index.htm. (Accessed 13 October 2015)
12. Mosholder, AD, Gelperin, K, Hammad, TA, Phelan, K, Johann-Liang, R, Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics 123 (2009), 611–616.
13. Cortese, S, Adamo, N, Del Giovane, C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5 (2018), 727–738.
14. Shyu, YC, Yuan, SS, Lee, SY, et al. Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population-based study in Taiwan. Schizophr Res 168 (2015), 161–167.
15. Man, KK, Coghill, D, Chan, EW, et al. Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system. Transl Psychiatry, 6, 2016, e956.
16. Ramstad, E, Storebø, O, Gerner, T, et al. Hallucinations and other psychotic symptoms in response to methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a Cochrane systematic review with meta-analysis and trial sequential analysis. Scand J Child Adolesc Psychiatr Psychol 6 (2018), 52–71.
17. Storebø, OJ, Pedersen, N, Ramstad, E, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents—assessment of adverse events in non-randomised studies. Cochrane Database Syst Rev, 5, 2018, CD012069.
18. Ludvigsson, JF, Otterblad-Olausson, P, Pettersson, BU, Ekbom, A, The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 24 (2009), 659–667.
19. Wettermark, B, Hammar, N, Fored, CM, et al. The new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16 (2007), 726–735.
20. Ludvigsson, JF, Andersson, E, Ekbom, A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health, 11, 2011, 450.
21. Ludvigsson, JF, Almqvist, C, Bonamy, AK, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol 31 (2016), 125–136.
22. Graham, J, Banaschewski, T, Buitelaar, J, et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 20 (2011), 17–37.
23. Viktorin, A, Ryden, E, Thase, ME, et al. The risk of treatment-emergent mania with methylphenidate in bipolar disorder. Am J Psychiatry 174 (2017), 341–348.
24. Storebø, OJ, Ramstad, E, Krogh, HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev, 5, 2015, CD009885.
25. Moran, LV, Ongur, D, Hsu, J, Castro, VM, Perlis, RH, Schneeweiss, S, Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med 380 (2019), 1128–1138.